Healthcare Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022 Updated Research Available

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

INDUSTRY
Healthcare

RELEASE DATE
25-Apr-2022
REGION
North America
DELIVERABLE TYPE
Frost Radar

RESEARCH CODE
MG76-01-00-00-00
SKU
HC03536-NA-MR_26474
Yes
SHARE

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022
Published on: 25-Apr-2022 | SKU: HC03536-NA-MR_26474

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink
Need more details?

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phases pushing through to FDA approval. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of targets and leads are inefficient.

Artificial intelligence (AI) is set to transform the drug discovery landscape. AI-based products and solutions are transforming drug discovery and development dynamics by enabling pharmaceutical players to shorten discovery timelines, enhance process agility, increase prediction accuracy on efficacy and safety, and improve the opportunity to diversify drug pipelines using a cost-effective model.

Most pharmaceutical vendors are focused on collecting, creating, and augmenting data from across laboratories, clinical trials, real-world evidence, biobanks, and repositories. The increasing volume and veracity of clinical and research data is compelling traditional providers to leverage enabling tools and technologies such as cloud computing, AI and machine learning, natural language processing, and advanced analytics to make a shift to a relatively fast, rational data-driven drug discovery and development approach.

To remain competitive, companies must strike the right balance of data, AI, and computational capability and match it with the wet lab capability. There remains inadequate understanding of the biological networks and drug-target interactions. Enter AI, which has been able to support the identification and prioritization of disease-specific therapeutic targets based on gene-disease associations. Such results must be replicated and validated through in vitro experiments and in vivo models.

Frost & Sullivan finds that the impact of AI on the entire pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of industry revenue, amounting to more than $50 billion in potential annual impact.

The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned.

Author: Aarti Siddhesh Chitale

Strategic Imperative

Strategic Imperative (continued)

Strategic Imperative (continued)

Growth Environment

Growth Environment (continued)

Frost Radar™: AI-enabled Drug Discovery

Frost Radar™: Competitive Environment

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

Frost Radar™: Competitive Environment (continued)

AbCellera Biologics

Atomwise

BenevolentAI

Berg Health

Black Diamond Therapeutics

Deep Genomics

Evaxion Biotech

Exscientia

Generate Biomedicines

GritstoneBio

Healx

Insilico Medicine

Insitro

Neumora Therapeutics

Recursion

Relay Therapeutics

Schrödinger

Valo Health

XtalPi

Strategic Insights

Significance of Being on the Frost Radar™

Frost Radar™ Empowers the CEO’s Growth Team

Frost Radar™ Empowers Investors

Frost Radar™ Empowers Customers

Frost Radar™ Empowers the Board of Directors

Frost Radar™: Benchmarking Future Growth Potential

Frost Radar™: Benchmarking Future Growth Potential

Legal Disclaimer

Frost Radar™: Benchmarking Future Growth Potential 2 Major Indices, 10 Analytical Ingredients, 1 Platform

Growth Index

Growth Index (GI) is a measure of a company’s growth performance and track record, along with its ability to develop and execute a fully aligned growth strategy and vision; a robust growth pipeline system; and effective market, competitor, and end-user focused sales and marketing strategies.

  • Market Share (previous 3 years)
    This is a comparison of a company’s market share relative to its competitors in a given market space for the previous 3 years.
  • Revenue Growth (previous 3 years)
    This is a look at a company’s revenue growth rate for the previous 3 years in the market/industry/category that forms the context for the given Frost Radar™.
  • Growth Pipeline
    This is an evaluation of the strength and leverage of a company’s growth pipeline system to continuously capture, analyze, and prioritize its universe of growth opportunities.
  • Vision and Strategy
    This is an assessment of how well a company’s growth strategy is aligned with its vision. Are the investments that a company is making in new products and markets consistent with the stated vision?
  • Sales and Marketing
    This is a measure of the effectiveness of a company’s sales and marketing efforts in helping it drive demand and achieve its growth objectives.

Innovation Index

Innovation Index (II) is a measure of a company’s ability to develop products/ services/ solutions (with a clear understanding of disruptive Mega Trends) that are globally applicable, are able to evolve and expand to serve multiple markets and are aligned to customers’ changing needs.

  • INNOVATION SCALABILITY
    This determines whether an organization’s innovations are globally scalable and applicable in both developing and mature markets, and also in adjacent and non-adjacent industry verticals.
  • RESEARCH AND DEVELOPMENT
    This is a measure of the efficacy of a company’s R&D strategy, as determined by the size of its R&D investment and how it feeds the innovation pipeline.
  • PRODUCT PORTFOLIO
    This is a measure of a company’s product portfolio, focusing on the relative contribution of new products to its annual revenue.
  • MEGATRENDS LEVERAGE
    This is an assessment of a company’s proactive leverage of evolving, long-term opportunities and new business models, as the foundation of its innovation pipeline.
  • CUSTOMER ALIGNMENT
    This evaluates the applicability of a company’s products/services/solutions to current and potential customers, as well as how its innovation strategy is influenced by evolving customer needs.

Significance of Being on the Frost Radar™

Companies plotted on the Frost RadarTM are the leaders in the industry for growth, innovation, or both. They are instrumental in advancing the industry into the future.

  • GROWTH POTENTIAL
    Your organization has significant future growth potential, which makes it a Company to Action.
  • BEST PRACTICES
    Your organization is well positioned to shape Growth Pipeline™ best practices in your industry.
  • COMPETITIVE INTENSITY
    Your organization is one of the key drivers of competitive intensity in the growth environment.
  • CUSTOMER VALUE
    Your organization has demonstrated the ability to significantly enhance its customer value proposition.
  • PARTNER POTENTIAL
    Your organization is top of mind for customers, investors, value chain partners, and future talent as a significant value provider.

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Healthcare research

28 Aug 2026   |   Global   |   Technology Research

Innovations and Growth Opportunities in Advanced Medical Devices, Artificial Intelligence Solutions, Digital Solutions, and Medical Imaging Solutions

The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, artificial intelligence solutions, digital solutions, and medical imaging solutions.

The issue features advanced medical devices such as active b...

27 Aug 2026   |   Global   |   Frost Radar

Frost Radar: AI-Powered Molecular Diagnostics, 2026

AI-powered molecular diagnostics is an emerging and moderately fragmented industry that includes molecular diagnostics companies, precision medicine platforms, sequencing specialists, AI-driven analytics providers, and disease-focused biotechnology companies. No single company has dominated, present...

26 Aug 2026   |   Global   |   Technology Research

Growth Opportunities and Advancements in Acute and Chronic Wound Care

A wound is any disruption in the normal structure and function of the skin or underlying tissues. It can result from physical injury, surgery, or underlying medical conditions. Wounds are broadly classified into two categories: acute wounds and chronic wounds. Acute wounds typically heal through the...

26 Aug 2026   |   Global   |   Frost Radar

Frost Radar™: Healthcare Infrastructure Cybersecurity in the United States, 2026

Healthcare organizations are expanding their digital environments across cloud infrastructure, connected medical devices, applications, identities, operational technology, and distributed care settings, creating a broader and increasingly interconnected attack surface. Cybersecurity is, therefore, e...

25 Aug 2026   |   Global   |   Technology Research

Breakthrough Innovations in Point-of-Care Diagnostics

This research analyzes how point-of-care (PoC) diagnostics is evolving from simple tests to decentralized, connected, and clinically actionable testing platforms across hospitals, outpatient settings, homes, and pharmacies.

The study assesses key technology shifts, including rapid molecular t...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

Pharmaceutical drug discovery and development has been suffering from declining success rates with new molecules primarily because of poor external validity of preclinical models and lack of efficacy of the molecule in terms of the intended disease indication. Drug success rates continue to be in the range of only 1 in 10 that enters clinical phases pushing through to FDA approval. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of targets and leads are inefficient. Artificial intelligence (AI) is set to transform the drug discovery landscape. AI-based products and solutions are transforming drug discovery and development dynamics by enabling pharmaceutical players to shorten discovery timelines, enhance process agility, increase prediction accuracy on efficacy and safety, and improve the opportunity to diversify drug pipelines using a cost-effective model. Most pharmaceutical vendors are focused on collecting, creating, and augmenting data from across laboratories, clinical trials, real-world evidence, biobanks, and repositories. The increasing volume and veracity of clinical and research data is compelling traditional providers to leverage enabling tools and technologies such as cloud computing, AI and machine learning, natural language processing, and advanced analytics to make a shift to a relatively fast, rational data-driven drug discovery and development approach. To remain competitive, companies must strike the right balance of data, AI, and computational capability and match it with the wet lab capability. There remains inadequate understanding of the biological networks and drug-target interactions. Enter AI, which has been able to support the identification and prioritization of disease-specific therapeutic targets based on gene-disease associations. Such results must be replicated and validated through in vitro experiments and in vivo models. Frost & Sullivan finds that the impact of AI on the entire pharma value chain can more than double what is achievable using traditional analytics and capture between 2% and 3% of industry revenue, amounting to more than $50 billion in potential annual impact. The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the Frost Radar™ methodology. The document presents competitive profiles on each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. Frost & Sullivan analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned. Author: Aarti Siddhesh Chitale
More Information
Deliverable Type Frost Radar
Author Aarti Siddhesh Chitale
Industries Healthcare
No Index No
Is Prebook No
Podcast No
WIP Number MG76-01-00-00-00

Frost Radar™: Artificial Intelligence-enabled Drug Discovery, 2022

$4,950.00

Special Price $3,712.50 save 25 %

In stock
SKU
HC03536-NA-MR_26474